Public Employees Retirement System of Ohio lowered its stake in Johnson & Johnson (NYSE:JNJ) by 6.3% during the second quarter, Holdings Channel.com reports. The firm owned 1,688,590 shares of the company’s stock after selling 112,657 shares during the quarter. Johnson & Johnson accounts for about 1.3% of Public Employees Retirement System of Ohio’s portfolio, making the stock its 7th largest position. Public Employees Retirement System of Ohio’s holdings in Johnson & Johnson were worth $235,187,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of JNJ. Charles Schwab Investment Management Inc. grew its stake in Johnson & Johnson by 1.7% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 12,399,820 shares of the company’s stock worth $1,727,047,000 after buying an additional 209,429 shares during the last quarter. Fisher Asset Management LLC grew its stake in Johnson & Johnson by 2.6% during the 2nd quarter. Fisher Asset Management LLC now owns 11,841,121 shares of the company’s stock worth $1,649,231,000 after buying an additional 301,124 shares during the last quarter. Clearbridge Investments LLC grew its stake in Johnson & Johnson by 0.5% during the 1st quarter. Clearbridge Investments LLC now owns 9,628,443 shares of the company’s stock worth $1,345,960,000 after buying an additional 48,582 shares during the last quarter. Nordea Investment Management AB grew its stake in Johnson & Johnson by 14.2% during the 1st quarter. Nordea Investment Management AB now owns 8,709,414 shares of the company’s stock worth $1,217,494,000 after buying an additional 1,079,751 shares during the last quarter. Finally, Prudential Financial Inc. grew its stake in shares of Johnson & Johnson by 8.1% in the 2nd quarter. Prudential Financial Inc. now owns 5,171,858 shares of the company’s stock valued at $720,336,000 after purchasing an additional 386,047 shares during the last quarter. 72.12% of the stock is currently owned by institutional investors.

Shares of JNJ stock traded down $0.32 during midday trading on Friday, hitting $130.11. The company had a trading volume of 1,656,706 shares, compared to its average volume of 7,701,360. The company’s 50 day simple moving average is $130.11 and its 200 day simple moving average is $135.97. Johnson & Johnson has a 52-week low of $121.00 and a 52-week high of $148.99. The stock has a market cap of $341.90 billion, a price-to-earnings ratio of 15.91, a PEG ratio of 2.19 and a beta of 0.68. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.33 and a quick ratio of 1.04.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, July 16th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.42 by $0.16. The business had revenue of $20.56 billion during the quarter, compared to analysts’ expectations of $20.39 billion. Johnson & Johnson had a return on equity of 38.63% and a net margin of 20.08%. The company’s quarterly revenue was down 1.3% compared to the same quarter last year. During the same period last year, the firm earned $2.10 EPS. Analysts anticipate that Johnson & Johnson will post 8.6 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th were issued a $0.95 dividend. The ex-dividend date of this dividend was Monday, August 26th. This represents a $3.80 annualized dividend and a dividend yield of 2.92%. Johnson & Johnson’s dividend payout ratio is currently 46.45%.

Several research analysts have weighed in on JNJ shares. Morgan Stanley reiterated an “equal weight” rating and issued a $145.00 target price on shares of Johnson & Johnson in a research note on Tuesday, August 27th. Credit Suisse Group set a $156.00 target price on Johnson & Johnson and gave the company a “buy” rating in a research note on Tuesday, August 27th. Raymond James lowered their target price on Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 17th. Bank of America reiterated a “hold” rating and issued a $150.00 target price on shares of Johnson & Johnson in a research note on Tuesday, July 16th. Finally, Zacks Investment Research downgraded Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 target price on the stock. in a research note on Thursday, July 18th. Five equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Johnson & Johnson presently has a consensus rating of “Buy” and an average price target of $150.60.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: How does quantitative easing work?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.